In contrast TP53 mutations in IPMNs are undetectable in IPMN hyperplasia or adenoma, whereas they become detectable in IPMN carcinoma at a rate of 38% to 50% [28], [29]. This evidence concerns the gene TP53 and pancreatic intraductal papillary-mucinous neoplasm.